SCHEMBL4958152

SCHEMBL4958152

CCOC(=O)c1ncn(Cc2ccccc2)c1C

nearest known ligand 0.54

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.54
GAA P10253 1/20 0.54
PKM P14618 1/20 0.54
CYP19A1 P11511 4/20 0.53
SMN1; SMN2 Q16637 2/20 0.52
RECQL P46063 1/20 0.52
MAPK10 P53779 1/20 0.52
ALDH1A1 P00352 3/20 0.50
LMNA P02545 1/20 0.50
EED O75530 1/20 0.49
MAPK1 P28482 2/20 0.49
TP53 P04637 1/20 0.49
ALOX12 P18054 1/20 0.49
NPC1 O15118 1/20 0.48
RAB9A P51151 1/20 0.48
KDM4E B2RXH2 1/20 0.47
POLB P06746 1/20 0.47
SCD O00767 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2145110 0.88 TSHR (0.52) TSHRGAAPKMCYP19A1SMN1; SMN2
SCHEMBL1753177 0.86 MAPK1 (0.55) TSHRGAAPKMCYP19A1SMN1; SMN2
SCHEMBL2145170 0.85 CYP19A1 (0.53) TSHRGAAPKMCYP19A1SMN1; SMN2
SCHEMBL10566878 0.84 ALDH1A1 (0.52) GAASMN1; SMN2RECQLMAPK10ALDH1A1
SCHEMBL4958156 0.84 PKM (0.69) TSHRGAAPKMSMN1; SMN2LMNA
SCHEMBL11213556 0.81 SMN1; SMN2 (0.55) TSHRGAAPKMCYP19A1SMN1; SMN2
SCHEMBL4505446 0.80 NPC1 (0.51) TSHRGAASMN1; SMN2RECQLMAPK10
SCHEMBL10567125 0.80 ALDH1A1 (0.51) TSHRSMN1; SMN2ALDH1A1LMNAEED
SCHEMBL17456271 0.78 SMN1; SMN2 (0.53) TSHRGAAPKMCYP19A1SMN1; SMN2
SCHEMBL1753091 0.78 SMN1; SMN2 (0.53) TSHRGAAPKMCYP19A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8937184-B2 1H-imidazole derivatives as cannabinoid CB2 receptor modulators ABBVIE B.V. (NL) 2015-01-20 US disclosed
EP-1874734-A1 1H-IMIDIAZOLE DERIVATIVES AS CANNABINOID CB2 RECEPTOR MODULATORS Solvay Pharmaceuticals B.V. (NL) 2008-01-09 EP disclosed
US-20060194779-A1 1H-imidazole derivatives as cannabinoid CB2 receptor modulators ABBVIE B.V. (NL) 2006-08-31 US disclosed
WO-2006087355-A1 1H-IMIDIAZOLE DERIVATIVES AS CANNABINOID CB2 RECEPTOR MODULATORS SOLVAY PHARMACEUTICALS B.V. (NL) 2006-08-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060194779-A1 1H-imidazole derivatives as cannabinoid CB2 receptor modulators CNR1, CNR2, HRH4 TSHR 590/4885GAA 4298/4885PKM 2851/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.